Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 11

Trial Status

Completed1

Role Distribution

Principal Investigator1
PI Rate100%

Activity Timeline

Clinical Trials (1)

NCT05116007Phase 1Completed
Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Chemotherapy in Patients With ES-SCLC
SCLC, Extensive Stage
PrincipalinvestigatorStart date: 2021-03-29

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Research Areas & Affiliations

Therapeutic Areas

Affiliations

Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiaotong University, P. R. China

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Ningbo Liu, Doctor

Tianjin Medical University Cancer Institute and Hospital

Moderately Similar
1 trials

Shared therapeutic areas:

SCLC, Extensive Stage
Similarity Score30%

Dong Wang, PH.D

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Moderately Similar
1 trials

Shared therapeutic areas:

SCLC, Extensive Stage
Similarity Score30%

Shuhang wang, PhD

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Moderately Similar
2 trials

Shared therapeutic areas:

SCLC, Extensive Stage
Similarity Score30%

Zhijie Wang, MD, PhD

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Moderately Similar
1 trials

Shared therapeutic areas:

SCLC, Extensive Stage
Similarity Score30%

Dingzhi Huang, M.D

Tianjin Medical University Cancer Institute and Hospital

Moderately Similar
1 trials

Shared therapeutic areas:

SCLC, Extensive Stage
Similarity Score30%

Yanqiu Zhao, MS

Henan Tumor Hospital

Moderately Similar
2 trials

Shared therapeutic areas:

SCLC, Extensive Stage
Similarity Score30%

Martin Reck, Prof. Dr.

LungenClinic Grosshansdorf

Moderately Similar
1 trials

Shared therapeutic areas:

SCLC, Extensive Stage
Similarity Score30%

Dingzhi Huang, Doctor

Tianjin Medical University Cancer Institute and Hospital

Moderately Similar
3 trials

Shared therapeutic areas:

SCLC, Extensive Stage
Similarity Score30%

Chunxia Su, Doctor

Shanghai Pulmonary Hospital, Shanghai, China

Moderately Similar
2 trials

Shared therapeutic areas:

SCLC, Extensive Stage
Similarity Score30%

Richard Greil, MD

AGMT gemeinnützige GmbH

Moderately Similar
3 trials

Shared therapeutic areas:

SCLC, Extensive Stage
Similarity Score30%

Publications (0)

No publications found for this investigator.

Clinical Trials (1)

Showing 1 of 1 trials

NCT05116007Phase 1PrincipalInvestigator

Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Chemotherapy in Patients With ES-SCLC

SCLC, Extensive Stage
Completed

All 1 trials loaded